Relmada Therapeutics, Inc. is a clinical-stage company focused on developing therapies for oncology and central nervous system (CNS) disorders. Headquartered in Coral Gables, Florida, the company advances a pipeline of novel chemical entities and repurposed drugs designed to address areas of high unmet medical need. The company's lead oncology asset is NDV-01, a controlled-release intravesical formulation of the chemotherapies gemcitabine and docetaxel, which is in Phase 2 clinical trials for non-muscle invasive bladder cancer. In its CNS pipeline, Relmada is developing sepranolone, a neurosteroid targeting conditions such as Prader-Willi syndrome and Tourette syndrome, as well as esmethadone (REL-1017), an NMDA receptor antagonist for depression. Relmada operates primarily in the United States and focuses on advancing its candidates through clinical trials and regulatory milestones.
